©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
The -Adrenergic Receptor Kinase (GRK2) Is Regulated by Phospholipids (*)

(Received for publication, June 12, 1995)

James J. Onorato (1)(§) Mary E. Gillis (1) Yu Liu (3) Jeffrey L. Benovic (2) Arnold E. Ruoho (3)

From the  (1)Department of Medicine, University of Wisconsin, Madison, Wisconsin 53706, the (2)Department of Pharmacology, Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, and the (3)Department of Pharmacology, University of Wisconsin, Madison, Wisconsin 53706

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

The beta-adrenergic receptor kinase (betaARK) is a member of growing family of G protein coupled receptor kinases (GRKs). betaARK and other members of the GRK family play a role in the mechanism of agonist-specific desensitization by virtue of their ability to phosphorylate G protein-coupled receptors in an agonist-dependent manner. betaARK activation is known to occur following the interaction of the kinase with the agonist-occupied form of the receptor substrate and heterotrimeric G protein beta subunits. Recently, lipid regulation of GRK2, GRK3, and GRK5 have also been described. Using a mixed micelle assay, GRK2 (betaARK1) was found to require phospholipid in order to phosphorylate the beta(2)-adrenergic receptor. As determined with a nonreceptor peptide substrate of betaARK, catalytic activity of the kinase increased in the presence of phospholipid without a change in the K for the peptide. Data obtained with the heterobifunctional cross-linking agent N-3[I]iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)cysteine ([I]ACTP) suggests that the activation by phospholipid was associated with a conformational change in the kinase. [I]ACTP incorporation increased 2-fold in the presence of crude phosphatidylcholine, and this increase in [I]ACTP labeling is completely blocked by the addition of MgATP. Furthermore, proteolytic mapping was consistent with the modification of a distinct site when GRK2 was labeled in the presence of phospholipid. While an acidic phospholipid specificity was demonstrated using the mixed micelle phosphorylation assay, a notable exception was observed with PIP(2). In the presence of PIP(2), kinase activity as well as [I]ACTP labeling was inhibited. These data demonstrate the direct regulation of GRK2 activity by phospholipids and supports the hypothesis that this effect is the result of a conformational change within the kinase.


INTRODUCTION

The molecular mechanisms involved in signal transduction of G protein-coupled receptors are best understood in the visual system where rhodopsin serves as the ``receptor'' for light (1) and the beta-adrenergic pathway in which the beta-adrenergic receptor (betaAR) (^1)binds catecholamines(2, 3) . A feature common to both model systems as well as many other G protein receptors is the diminished responsiveness with time to a signal of equal intensity. This phenomenon is known as desensitization (4) and exhibits both an agonist-specific and nonspecific pattern. Rapid, agonist-specific desensitization of rhodopsin and the beta(2)-adrenergic receptor (beta(2)AR) occurs in response to the phosphorylation of the receptor by the enzymes rhodopsin kinase and the beta-adrenergic receptor kinase (betaARK)(5) . Rhodopsin kinase and betaARK are members of a family known as G protein-coupled receptor kinases (GRKs). A common feature to the GRK family of kinases is multi-site phosphorylation of receptor substrates in response to agonist occupancy(6) . The relationship between agonist occupancy and receptor phosphorylation by GRKs is key to the specificity of the desensitization process, while other kinases such as protein kinase A and C play a role in nonspecific or heterologous desensitization. Two possible mechanisms could explain the enhanced phosphorylation of the activated form of the receptor by kinases of the GRK family. First, receptor occupancy may induce a conformational change exposing potential phosphorylation sites previously sequestered from the kinase. Alternatively, interaction of the kinase with the agonist-bound form of the receptor could result in enhanced catalytic activity of the kinase. The bulk of the experimental evidence supports the latter hypothesis(7, 8, 9) . In addition to the enhanced catalytic activity of GRKs in the presence of agonist-occupied receptor, GRK2 and GRK3 activity is also increased by heterotrimeric G protein beta subunits(10, 11, 12, 13) . The potential for finely controlled desensitization by the interplay of receptors and beta subunits is an exciting possibility given the evidence for dual regulation of GRK2 and GRK3 by these proteins(14) .

While G protein-coupled receptors serve as substrates for the kinase after reconstitution into phospholipid vesicles, only recently has specific lipid requirements for GRKs been described. GRK5 was reported to require phospholipid for maximal catalytic activity(15) . In this case, phospholipid-stimulated autophosphorylation of GRK5 was necessary for phosphorylation of the beta(2)AR and rhodopsin. In addition, GRK2 and GRK3 were regulated by phospholipids via the interaction with the carboxyl-terminal portion of the kinase known as the pleckstrin homology domain(16, 17) . In the initial report, the incorporation of negatively charged lipids into phospholipid vesicles resulted in a physical interaction of GRK2 or GRK3 with the vesicle. With the exception of PIP(2), this resulted in enhance phosphorylation of the human m2 muscarinic acetylcholine receptor. The addition of PIP(2) resulted in inhibition of phosphorylation of the receptor in a competitive manner with respect to other phospholipids. Purified heterotrimeric G protein beta subunits were able to reverse this inhibition. Furthermore, the lack of additivity suggested a common site of interaction on the kinase for the lipids and G protein beta subunits. This hypothesis was further supported by the finding that two previously characterized G protein beta subunit binding proteins, phosducin and glutathione S-transferase-betaARK(466-689) fusion protein, prevented the effects of the phospholipids. In a subsequent report, similar effects in terms of PIP(2)-enhanced binding of GRK2 to phospholipid vesicles was described. In contrast to the previous manuscript, data are presented that demonstrate increased GRK2 activity when coincubated with both PIP(2) and G protein beta subunits. Additionally, the remaining lipids previously reported to increase kinase activity in the absence of beta subunits in this case required the addition of G protein beta subunits to enhance GRK2 activity. The interpretation by these authors was that effective membrane localization of betaARK, which enhanced both the rate and extent of phosphorylation of receptor substrates, required the simultaneous presence of two pleckstrin homology domain ligands.

In this manuscript, we provide evidence of an acidic phospholipid requirement of GRK2 based on the phosphorylation of dodecyl maltoside-solubilized receptors and the direct activation of the kinase toward peptide substrates by the addition of various phospholipids. Additionally, lipids that failed to enhance kinase activity did not increase labeling of GRK2 with the the heterobifunctional reagent [I]ACTP. Finally, data obtained in the absence of G protein beta subunits agree with the original report in which PIP(2) promotes kinase binding to phospholipid vesicles but inhibits enzymatic activity(16) . Thus, we provide evidence for catalytic activation as well as a conformational change in GRK2 following the interaction of the kinase and phospholipid. These data raise the possibility of a third level of regulation of GRK2 activity within the cell and suggest that the mechanism of phospholipid is more complex than simply targeting of the kinase to the plasma membrane.


EXPERIMENTAL PROCEDURES

Materials

Isoproterenol, alprenolol, and all phospholipids were purchased from Sigma. Western blot detection reagents including donkey anti-rabbit horseradish peroxidase-conjugated secondary antibody was obtained from Amersham Corp. The peptide substrate (RRREEEEESAAA) was synthesized using t-butoxycarbonyl chemistry with an Applied Biosystems 430A peptide synthesizer. Prior to use, the synthetic peptide was purified by reverse phase high performance liquid chromatography using a C-18 column and a 0-50% acetonitrile gradient in 0.1% trifluoroacetic acid/water. [-P]ATP, NaI, and [I]iodocyanopindolol were obtained from DuPont NEN. All other reagents were of the the highest commercial grade available.

Preparation of betaARK

betaARK (GRK2) was overexpressed and purified from Sf9 cells using the baculovirus expression system as previously detailed(18) . Briefly, cells were harvested 48 h after infection by low speed centrifugation. Following homogenization in 20 mM Hepes, pH 7.2, 250 mM NaCl, 5 mM EDTA, 3 mM phenylmethylsulfonyl fluoride, and 3 mM benzamidine, a high speed supernatant was prepared. The soluble fraction was diluted and applied to a SP-Sepharose column, which was washed and eluted in a 50-300 mM NaCl linear gradient. Peak activity fractions were pooled, diluted, and loaded on a heparin-Sepharose column. The betaARK was eluted from the heparin column using a 100-600 mM NaCl gradient. The peak activity was pooled and made 0.02% final in Triton X-100 and stored at 4 °C. Protein concentration was determined by the method of Bradford (19) using purified bovine serum albumin as a standard. Purity of the betaARK preparation was determined by SDS-polyacrylamide gel electrophoresis and was routinely >95%.

Preparation of beta(2)AR

The hamster beta(2)AR was expressed in Sf9 cells using the baculovirus system and purified on an alprenolol-Sepharose column using a modification of previously described techniques(20, 21) . n-Dodecyl beta-D-maltoside (10 mM) in 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10 µg/ml each of leupeptin, benzamidine, pepstatin A, and soybean trypsin inhibitor, along with 1 mM phenylmethylsulfonyl fluoride was used to effect solubilization of the receptor from the Sf9 cell pellet. Following a high and low salt wash of the alprenolol Sepharose column, the beta(2)AR was eluted into 50 ml of 1 mM dodecyl maltoside, 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 5 mM EDTA containing 100 µM(-)-alprenolol. The receptor was concentrated to 2 ml by ultrafiltration on a YM-30 or YM-100 membrane (Amicon) and stored at -80 °C.

For reconstitution studies, the purified receptor was reinserted into phosphatidylcholine vesicles, pelleted by centrifugation, and resuspended in 20 mM Tris-HCl, pH 7.4, 2 mM EDTA as described previously(22) . The concentration of receptor was determined using the beta-adrenergic receptor antagonist [I]iodocyanopindolol.

For studies in mixed detergent-lipid micelles, the purified receptor was diluted in 1 mM dodecyl maltoside, 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 5 mM EDTA and concentrated on a YM-100 membrane using a centricon device (Amicon). Alternatively, receptor purified in digitonin underwent detergent exchange on a G-50 column equilibrated in 0.5 mM dodecyl maltoside, 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, 5 mM EDTA and concentrated on a YM-100 membrane using a centricon device. Crude phosphatidylcholine vesicles were produced using a tip sonicator with three 1-min bursts on ice. The desired amount of beta(2)AR was added to various amounts of phospholipid in 20 mM Tris-HCl, pH 7.4, 2 mM EDTA. Other phospholipids, stored as stock solutions in chloroform, were first dried under a stream of N(2). The desired amount of phospholipid was mixed with dodecyl maltoside-solubilized beta(2)AR, from which alprenolol had been removed as described above, prior to use in the phosphorylation assay.

Phosphorylation of the beta(2)AR

Reconstituted beta(2)AR (0.03-0.5 pmol) was incubated with GRK2 in a total volume of 25-50 µl containing 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 7.5 mM MgCl(2), 0.1 mM [-P]ATP (200-1,000 cpm/pmol) at 30 °C. When indicated,(-)-isoproterenol was included at a final concentration of 10-50 µM. The reaction was stopped by the addition of 50 µl of SDS-PAGE stop solution and the receptor resolved on 9 or 12% polyacrylamide gels(23) . Phosphorylated beta(2)AR was visualized by autoradiography, and the corresponding bands were excised and counted to determine the extent of phosphate incorporation. Unlike some previous studies with reconstituted receptor, no correction factor for the stoichiometry of receptor phosphorylation was used in these studies.

Phosphorylation of dodecyl maltoside-solubilized beta(2)AR was performed in the presence or absence of crude phosphatidylcholine or various purified phospholipids in a buffer of 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 7.5 mM MgCl(2), 0.1 mM [-P]ATP (200-1,000 cpm/pmol). The final volume was 50 µl, and the phosphorylation reaction was carried out at 30 °C for various times as indicated. The reaction was stopped, and the phosphate incorporation was determined as detailed above.

Phosphorylation of Synthetic Peptides

A stock solution of purified synthetic peptides was prepared, and the pH was adjusted to 7.4 by the addition of Tris base. The peptides were incubated with GRK2 (80 ng/assay tube) in a buffer containing 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 0.1 mM [-P]ATP (200-1,000 cpm/pmol), 7.5 mM MgCl(2) in a final volume of 25 µl at 30 °C. The reaction was stopped by transferring the entire reaction mixture to a 2 2-cm square of P-81 paper followed by six washes in 75 mM phosphoric acid (10 ml/square). GRK2 activity was defined as the difference in phosphate incorporation in the presence and absence of peptide. Similar results are obtained if the kinase activity was determined in the presence or absence of GRK2. As phosphorylation reactions exhibited a higher blank when performed in the presence of added phospholipid, separate blanks were determined for assays in the absence or presence of additional phospholipid. A nonlinear regression program (Enzfitter, Elsevier-Biosoft, Cambridge, UK) was used to estimate the kinetic parameters.

[I]ACTP Labeling

[I]ACTP was synthesized as described previously by Dhanasekaran et al.(24) . GRK2 (8 µg or 0.1 nmol) is reacted with an excess (1-200-fold) of [I]ACTP in dimethylformamide (final concentration of DMF is <10%). After a 120-min incubation in the dark at 4 °C, the reaction was stopped by the addition of SDS (2% final) and 40 mMN-ethylmaleimide. The labeled kinase band was resolved by SDS-PAGE under nonreducing conditions. The GRK2 band was localized by autoradiography, excised, and counted. The stoichiometry was calculated after determining the specific activity of the [I]ACTP preparation (typically 1 Ci/mmol).

Immunodetection of GRK2

Polyacrylamide gels were transferred overnight to nitrocellulose membranes. Immunodetection of GRK2 was performed using a rabbit antisera raised to purified betaARK1 at a 1:4,000 dilution. Detection of the GRK2 using horseradish peroxidase conjugated donkey anti-rabbit antibody was as described by the manufacturer (Amersham Corp.).


RESULTS

A unique feature of the GRK family is the ability to phosphorylate the agonist-occupied form of a variety of G protein-coupled receptors. In order for a receptor to serve as a substrate for betaARK, the protein is typically purified and reinserted into phospholipid vesicles. If phosphorylation of the receptor in detergent is attempted, no significant incorporation of phosphate is observed. Based on binding data, the receptor exhibits appropriate binding properties and is not degraded. While the possibility exists that detergents inhibit the kinase or reconstitution into bulk lipid provides a conformational structure required for interaction with GRKs, only recently have specific lipid requirement for GRKs been described(15, 16, 17) . Fig. 1demonstrates the phosphorylation of the beta(2)AR in dodecyl maltoside by GRK2. The phosphorylation of the receptor requires the addition of crude phosphatidylcholine and is stimulated by the addition of beta-adrenergic agonist. The stoichiometry of phosphorylation is maximal at 4-5 mol of phosphate/mol of receptor. In data not shown, the effect of isoproterenol is blocked by the addition of the beta-adrenergic receptor antagonist alprenolol. Also, there is a linear dependence between the amount of beta(2)AR added to the reaction mixture and the phosphate incorporation observed after resolving the receptor by SDS-PAGE with the maximal stoichiometry remaining 4 mol phosphate/mol receptor. Finally, the phosphorylated receptor is not pelleted by a 300,000 g centrifugation step in contrast to reconstituted receptor.


Figure 1: Phosphorylation of detergent-solubilized beta(2)-adrenergic receptor by GRK2. beta(2)AR is expressed in Sf9 cells, solubilized in dodecyl maltoside, and purified by affinity chromatography using an alprenolol-Sepharose column. Alprenolol is removed by size-exclusion chromatography on a G-50 column in 100 mM NaCl, 10 mM Tris-HCl, pH 7.4, and 1 mM dodecyl maltoside. The receptor is then concentrated using a Centricon-100 ultrafiltration device prior to phosphorylation. Receptor phosphorylation is carried out as described in the text, and the reaction is quenched by the addition of SDS sample buffer. The receptor is resolved by 9% SDS-polyacrylamide gel electrophoresis followed by autoradiography. The phosphorylation reaction is performed in the presence (lanes1 and 2) or absence (lane3) of crude phosphatidylcholine (50 µg). Isoproterenol (50 µM) is added (lanes2 and 3) to demonstrate the agonist dependent nature of receptor phosphorylation by GRK2. The stoichiometry of phosphorylation is determined by excising the receptor band, quantitating the P and expressing the data as mol of phosphate/mol of beta(2)AR.



In order to define the phospholipid specificity of the GRK2 phosphorylation reaction, solubilized beta(2)AR is added to a variety of neutral, acidic, and basic phospholipids. As shown in Fig. 2, only lipids with a net negative charge including cardiolipin, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and phosphatidylinositol support the phosphorylation of the beta(2)AR by GRK2. The addition of crude, but not purified, phosphatidylcholine results in receptor phosphorylation. This suggests that a phospholipid other than phosphatidylcholine is responsible for the activation of GRK2 observed above. Fig. 3compares the effects of phosphatidylinositol to those of PIP(2). While phosphatidylinositol enhanced receptor phosphorylation by GRK2, there is no significant beta(2)AR phosphorylation in mixed micelles containing PIP(2).


Figure 2: Phospholipid specificity of beta(2)AR phosphorylation by betaARK. 2.5 µl of a phospholipid (10 mg/ml stock in chloroform) is taken to dryness with a stream of nitrogen gas and rehydrated with 10 µl of 20 mM Tris-HCl, pH 7.2, 2 mM EDTA, and 1 mM dodecyl maltoside at 30 °C. Mixed micelles are formed by the addition of Alprenolol-free beta(2)AR. The final volume of the phosphorylation reaction is 50 µl and contained 2.8 pmol of receptor. The phosphorylation reaction is begun by the addition of kinase and ATP at 30 °C and stopped after 60 min with 10 µl of the SDS-PAGE stop solution. 20-µl aliquots were loaded on a 12% polyacrylamide gel, and the phosphorylated receptor was localized by autoradiography. The samples are as follows: lane 1, no lipid (incubation performed in the absence of 10 µM isoproterenol); lane 2, no lipid; lane 3, crude phosphatidylcholine (incubation performed in the absence of 10 µM isoproterenol); lane 4, crude phosphatidylcholine; lane 5, cardiolipin; lane 6, lysophosphatidylcholine; lane 7, palmitic acid; lane 8, phosphatidyl-DL-glycerol; lane 9, purified phosphatidylcholine; lane 10, phosphatidylethanolamine; lane 11, sphingomyelin; lane 12, phosphatidic acid; lane 13, phosphatidyl-L-serine; lane 14, phosphatidylinositol.




Figure 3: Effect of PIP(2) on GRK2 phosphorylation of the beta(2)AR.2.5 µl of phosphatidylinositol, PIP(2) (10 mg/ml stock in chloroform), or chloroform are taken to dryness with a stream of nitrogen gas and rehydrated with 10 µl of 20 mM Tris-HCl, pH 7.2, 2 mM EDTA, and 1 mM dodecyl maltoside at 30 °C. beta(2)AR phosphorylation by GRK2 in mixed micelles is performed as described above in the presence or absence of 10 µM isoproterenol.



To further investigate the effect of phospholipid on GRK2 activity, a nonreceptor peptide substrate (RRREEEEESAAA) previously shown to serve as a betaARK1 substrate is used(25) . The time course of phosphorylation of the peptide by GRK2 is linear for 2 h in the absence or presence of phospholipid (Fig. 4). However, there is a substantial increase in phosphate incorporation observed with the addition of crude phosphatidylcholine to the reaction mixture. The effect of phosphatidylcholine is not due to protection of the kinase from degradation or other nonspecific effects as Western blotting reveals equal amounts of the 80,000 M(r) kinase band without evidence of proteolytic cleavage (data not shown).


Figure 4: Time course of synthetic peptide phosphorylation by GRK2. The synthetic peptide substrate RRREEEEESAAA (1 mM) is incubated for various times as indicated in the presence () or absence (bullet) of crude phosphatidylcholine (50 µg). The reaction is stopped by spotting the sample on a square of P-81 ion-exchange paper and washing in phosphoric acid as described. Each sample is performed in triplicate, and the results shown are that of a typical experiment.



The kinetic parameters of phosphorylation are determined in the presence of varying amounts of the peptide substrate. As shown in Table 1, the effect of phospholipid is to increase the V(max) of the phosphorylation reaction approximately 3-fold (8.7-25.4 nmol/minbulletmg of betaARK) without a change in the K for the peptide substrate. In data shown in Table 2, phosphatidylinositol increased phosphorylation of the peptide substrate 6-fold while PIP(2) decreased GRK2 activity to 30% of the control level.





As GRK5, a member of the GRK family related to betaARK, has been shown to undergo phospholipid-stimulated autophosphorylation and association with phospholipid vesicles(15) , we examine GRK2 to determine if a similar mechanism may be responsible for the phospholipid activation of the kinase. GRK2 does not autophosphorylate to any significant degree in the presence or absence of crude phosphatidylcholine (Fig. 5). At 1 h, the maximal amount of autophosphorylation is observed with a stoichiometry of 0.1 mol phosphate/mol kinase. A Western blot of GRK2 incubated with vesicles prepared from purified lipids demonstrates a significant amount of immunoreactivity associated with the pellet (Fig. 6). 10-20% of the immunoreactive GRK2 did pellet with phosphatidylinositol, and 5% pelleted with PIP(2). These data stand in contrast to that seen with GRK5 (15) and suggest different mechanisms of lipid activation of the two kinases. Moreover, the demonstration of GRK2 association with vesicles containing either phosphatidylinositol or PIP(2) is in agreement with the previously published findings(16, 17) .


Figure 5: Autophosphorylation of GRK2. Autophosphorylation of GRK2 is determined under conditions identical to receptor phosphorylation studies containing 80 ng (1 pmol) of purified GRK2 with () or without (bullet) added crude phosphatidylcholine (50 µg). The kinase is resolved by SDS-PAGE and localized by autoradiography. The gel slice containing the GRK2 band is excised and counted to determine the stoichiometry of phosphorylation, which is expressed as mol of phosphate/mol of GRK2.




Figure 6: Effect of lipids on GRK2 binding to phospholipid vesicles. Lipids are dried under a stream of nitrogen and resuspended in 20 mM Tris-HCl, pH 7.2, 2 mM EDTA with three bursts of a tip sonicator. GRK2 (1 pmol) is added, and the mixture is incubated on ice for 15 min. The phospholipid vesicles are collected by centrifugation at 15,000 g for 30 min. The supernatants and corresponding phospholipid pellets analyzed by SDS-PAGE and GRK2 were detected by immunoblotting. GRK2 binding to phosphatidylcholine and PIP(2) vesicles as well as a control lane representing the total amount of kinase used in each incubation is shown.



The heterobifunctional cross-linking reagent, N-3-[I]iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)cysteine has been used to map the molecular structure of transducin's alpha subunit(24) . Under mild, nondenaturing conditions, [I]ACTP derivatizes reduced sulfhydryls to form a mixed disulfide easily cleaved by the addition of excess reducing agents. When GRK2 is incubated for 2 h in the dark with a 100-fold molar excess of [I]ACTP relative to kinase, there is incorporation of 1 mol [I]ACTP/mol kinase. The addition of phospholipid vesicles to the reaction results in a 2-fold enhancement of incorporation to a stoichiometry of 2 mol of [I]ACTP/mol of betaARK1 (Fig. 7). The additional [I]ACTP incorporation observed in the presence of phospholipid vesicles is blocked by the addition of MgATP at concentrations identical to those used in the phosphorylation assay. The effect of MgATP was specific for [I]ACTP in response to phospholipid as there is no effect observed with [I]ACTP incorporation in the absence of phospholipid. In all cases, the [I]ACTP incorporation is sensitive to reducing agents, indicating the presence of a mixed disulfide and not covalent attachment via the azide moiety. When a variety of lipids are examined, only the acidic phospholipids previously shown to enhance GRK2 activity led to an increase in [I]ACTP labeling of the kinase (Fig. 8). Of note is the observation that PIP(2) not only failed to increase the labeling of GRK2, but decreased [I]ACTP incorporation to a level below that seen in the basal state. A preliminary mapping experiment demonstrates that the I associated with GRK2 resulted in a unique proteolytic map when cleaved with V-8 protease. The appearance of proteolytic bands of 14 and 6 kDa are observed when the kinase is labeled in the presence of the activating lipid phosphatidic acid (Fig. 9). These cleavage products are greatly diminished by co-incubation of lipid and MgATP or with the omission of the phospholipid to the labeling reaction (data not shown).


Figure 7: [I]ACTP labeling of GRK2. A 100-fold excess of [I]ACTP relative to kinase is incubated in the dark on ice for 2 h. The labeling is stopped by the addition of 2% SDS and 40 mMN-ethylmaleimide (final concentrations). SDS sample buffer without beta-mercaptoethanol is added and the GRK2 resolved under nonreducing conditions by SDS-PAGE. Fig. 7is a autoradiograph under basal (lane1), 50 µg crude phosphatidylcholine (lane2), MgCl(2) (7.5 mM) and ATP (0.1 mM) (lane3), and phosphatidylcholine and MgATP (lane4) conditions. The GRK2 band is excised and [I]ACTP incorporation determined by counting. The specific activity of the [I]ACTP varied with each preparation and is determined separately. These results are representative of [I]ACTP labeling performed a minimum of 4 times.




Figure 8: Lipid profile of [I]ACTP incorporation into GRK2. GRK2 is incubated with a 100-fold molar excess of [I]ACTP and the addition of 50 µg of various lipids as described above. The reaction is terminated by the addition of N-ethylmaleimide and SDS, and the kinase band is resolved by electrophoresis. An autoradiograph of labeled GRK2 is shown.




Figure 9: Proteolytic digest of [I]ACTP labeled GRK2. GRK2 is labeled is the absence(-) or presence (+) of phosphatidic acid (50 µg) as described above. The reaction is stopped by the addition of N-ethylmaleimide (40 mM) and [I]ACTP-labeled GRK2 digested with V-8 protease (1:10 ratio by weight) for the times indicated at 30 °C. The digest is stopped by the addition of SDS-sample buffer without beta-mercaptoethanol. The peptide fragments are resolved on a 10-20% SDS-PAGE gradient. [I]ACTP-labeled fragments are identified by autoradiography. The majority of unincorporated [I]ACTP is removed by desalting on a G-50 column in 20 mM Tris-HCl, pH 7.2, 2 mM EDTA, 0.02% Triton X-100 before proteolysis.




DISCUSSION

Regulation of G protein-coupled receptor function involves the process of desensitization in which a cell exposed to an agonist becomes less sensitive to subsequent stimulation. In the beta(2)AR-adenylyl cyclase system, nonselective, and agonist-specific forms of desensitization occur and appear to be related to phosphorylation of the receptor(26) . Kinases of the GRK family are thought to play a role in rapid, agonist-specific desensitization, as these enzymes phosphorylate the receptor in an agonist-dependent fashion. Several lines of evidence support this proposed role of GRKs in the desensitization process. First, cells that express beta(2)ARs that have had the putative GRK2 phosphorylation sites deleted exhibit delayed desensitization(27) . Second, a permeabilized cell system has been used to demonstrate that heparin, a potent inhibitor of GRK2, blocked both agonist-induced receptor phosphorylation and desensitization(28) . Third, type-specific antibodies directed toward GRK3 attenuated odorant-induced desensitization in olfactory cells(29, 30) . Fourth, Ishii et al.(31) have shown that GRK3 blocks thrombin signaling when the receptor and kinase are coexpressed in Xenopus oocytes. Finally, overexpression of a GRK2 dominant negative mutant in airway epithelial cells attenuates desensitization of the beta(2)AR(32) . At this time, these data are consistent with a role of GRK-mediated receptor phosphorylation in the process of agonist-specific desensitization.

The agonist-dependent phosphorylation of receptors by GRK2 and other members of the GRK family is a key feature of this class of enzymes. A conformational change in the receptor could expose potential phosphate acceptor sites to the kinase resulting in agonist-dependent phosphorylation of the receptor. However, this does not appear to be the mechanism involved in receptor-GRK interactions(7) . Alternatively, the kinase appears to interact with the agonist-occupied form of the receptor, which primarily results in an increase in the V(max) of the enzyme(8, 9) . Presumably, a conformational change occurs in GRK2 and other GRKs, which results in enhanced catalytic efficiency. Recently, it has been shown that the peptide mastoparan increases the activity of rhodopsin kinase (8) and a GRK isolated from porcine brain with properties similar to betaARK1(13) . Since mastoparan activates G proteins by mimicking a structure similar to agonist-occupied receptors(33) , a similar mechanism would seem likely in the stimulation of kinase activity.

In addition to the activation of the kinase following the interaction with agonist-occupied receptors, GRKs also interact with membranes via different mechanisms. Photostimulation of rhodopsin results in the association of rhodopsin kinase with the retinal membrane. The translocation to the membrane requires the farnesylation of rhodopsin kinase, a post-translational modification unique to this member of the GRK family(6) . GRK2 (betaARK1), GRK3 (betaARK2), and a related kinase from porcine brain all exhibit enhanced phosphorylation of agonist-occupied receptors in the presence of beta-subunits from heterotrimeric G proteins(10, 11, 12) . The effect of exogenous beta-subunits is to increase the rate and maximal stoichiometry of phosphorylation(11, 12) . This effect is synergistic with the activation of the kinase by agonist-occupied receptor or mastoparan (13) . Similarly to rhodopsin kinase, betaARK1 activity has been shown to translocate from the cytosol to the plasma membrane following stimulation of the target cell with a wide variety of agonists including isoproterenol, PGE(1), somatostatin, and platelet activating factor(34, 35, 36) . Unlike rhodopsin kinase, GRK2 does not undergo isoprenylation(37, 38) . However, the interaction of the kinase with the beta-subunits appears to target betaARK to the membrane(11) . Thus, two different molecular mechanisms exist for localizing GRKs to a membrane surface. Most recently, a third member of the GRK family (GRK5) was cloned and found to lack the sequence required for either isoprenylation or interaction with beta-subunits(15) . Consistent with the later is the finding that beta(2)AR or rhodopsin phosphorylation by GRK5 is not enhanced by the addition of beta-subunits. However, phospholipid-stimulated autophosphorylation of GRK5 at Ser-484 and Thr-485 increased receptor phosphorylation 15-fold and represents yet a third mechanism for membrane association of GRKs.

Despite the experimental data, which demonstrate the importance of phospholipid associations between GRKs, a clear effect of phospholipids is only now beginning to emerge. The observation that G protein-coupled receptors serve as substrates of GRKs following reconstitution into phospholipid vesicles or if expressed in high numbers in the plasma membrane of cells such as Sf9 insect cells (39) suggests the importance of lipids in the phosphorylation of receptor substrates. The traditional detergent for the solubilization of beta(2)ARs has been digitonin(20) . While biologic activity is preserved, the digitonin is difficult to remove due to its low critical micellar concentration (CMC). Furthermore, digitonin tends to concentrate with most ultrafiltration techniques. We have used dodecyl maltoside to effect solubilization and purification of the beta(2)AR. Dodecyl maltoside has a defined critical micellar concentration and forms micelles of 50,000 Da. We have taken advantage of these properties to concentrate the purified receptor using a YM-100 membrane. Under these conditions, detergent passes through while detergent-receptor micelles are retained by the membrane. In this manner, we could manipulate the receptor preparation without excessive concentration of the detergent. In addition, enzymatic activity of rhodopsin kinase (40) and betaARK1 (^2)is minimally affected by dodecyl maltoside while other detergents completely inhibit kinase activity despite concentrations below the critical micellar concentration of the detergent.

In the current study, we clearly demonstrate that detergent-solubilized beta(2)AR serves as a substrate for GRK2, provided phospholipid is added to the phosphorylation reaction. Under the conditions used in this study, the receptor resides in a mixed detergent-lipid micelle. The concentration of detergent used would not permit the formation of pure lipid vesicles typical of previous reconstitution experiments. Furthermore, the receptor under these conditions does not pellet following a 300,000 g centrifugation step adding support to the notion that the receptor is present in mixed micelles. This data would suggest that GRK2 has a phospholipid requirement for phosphorylation of receptor substrates. Using a variety of neutral, acidic, and basic phospholipids, we clearly demonstrate that negatively charged phospholipids, including cardiolipin, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and phosphatidylinositol, were necessary for phosphorylation of the beta(2)AR by GRK2. Previously, purified receptor was first inserted into crude phosphatidylcholine vesicles in order to observe GRK2-dependent phosphorylation. Therefore, we initially performed studies of phospholipid requirements of GRK2 using the same preparation of crude phosphatidylcholine. The fact that crude, but not purified, phosphatidylcholine preparations resulted in kinase activity is consistent with the notion that a phospholipid(s) other than phosphatidylcholine is required by GRK2. Thus, the long recognized requirement for reconstitution of the beta(2)AR into phosphatidylcholine vesicles most likely serves to provide a source of negatively charged phospholipid to the phosphorylation reaction.

As mentioned above, the lipid profile demonstrates that phospholipids with a net negative charge at physiologic pH enhance the phosphorylation of the beta(2)AR when studied in mixed detergent lipid micelles. A notable exception is the effect of PIP(2), as receptor phosphorylation is not observed when this phospholipid is included in the phosphorylation assay. Similar data has recently been reported when phosphorylation of the m2 muscarinic acetylcholine receptor was studied in reconstituted lipid vesicles (16) . In contrast, others reported that PIP(2) enhanced GRK2 phosphorylation of the beta(2)AR only in the presence of added beta subunits of heterotrimeric G proteins(17) . While the stoichiometry of phosphorylation is rather low compared with that previously reported using crude phosphatidylcholine, qualitatively similar results were noted for a variety of lipids tested. In contrast to our findings and that of DebBurman et al.(16) , in which >4 mol of phosphate/mol of receptor was achieved in the absence of beta subunits, a recent manuscript (17) indicated the stoichiometry was < 0.5 mol of phosphate/mol of beta(2)AR without the addition of G protein beta subunits.

The initial step in the mechanism of lipid regulation of GRK2 activity must involve the interaction between lipid and the kinase or the receptor. Evidence of a specific lipid-kinase interaction is provided by the finding that GRK2 becomes associated with vesicles provided they contain negatively charged lipids such as phosphatidylserine, phosphatidylinositol, or PIP(2). However, the phosphorylation data presented in this manuscript as well as that previously reported (16) suggests that the effects of lipids are more complex than simply targeting the kinase to the membrane surface. This is evident by the the effect of PIP(2) to cause membrane association in addition to inhibition of receptor phosphorylation.

In order to test the hypothesis that GRK2 activity is increased by phospholipids, we used a previously characterized peptide substrate of betaARK(25) . The advantage of the peptide substrate was 2-fold. First, the peptide substrate was designed to bind to ion exchange paper in 75 mM phosphoric acid permitting a large number of phosphorylation reactions necessary to obtain kinetic data. Second, the peptide substrate permits the identification of direct effects of phospholipid upon the kinase in the absence of any possible phospholipid-receptor interactions. The catalytic activity increases 3-fold with respect to the peptide substrate without a change in the K in the presence of crude phosphatidylcholine. We determined the kinetic parameters using crude phosphatidylcholine as this was the source of lipid that has been used for years in the reconstitution assay. Knowing that the crude preparations were 20% phosphatidylcholine and the results that demonstrate that crude but not purified phosphatidylcholine resulted in receptor phosphorylation in the mixed micelle system, we suspect that other phospholipids were responsible for betaARK activity in the reconstitution assay. As further support, we demonstrate that the inclusion of phosphatidylinositol to the peptide assay results in a dramatic enhancement of phosphate incorporation. Moreover, PIP(2) inhibited the ability of GRK2 to phosphorylate the synthetic peptide substrate, consistent with our data and that of others(16) , in which receptor phosphorylation was studied. In general, peptides are poor substrates for GRKs when compared with reconstituted receptors based on their low affinity for the kinase; however, they provide valuable data as to the mechanism of GRK activation. In this situation, the simplest explanation of the data is that GRK2 is directly activated following interaction with phospholipid. This observation would explain in part the apparent requirement for G protein-coupled receptors to be reconstituted into phospholipid vesicles in order to serve as GRK2 substrates.

Finally, we have used [I]ACTP as a probe to assess conformational changes that may occur in the kinase. We have observed that GRK2 will incorporate 1 mol of ACTP/mol of kinase under basal conditions. In the presence of crude phosphatidylcholine, the stoichiometry of [I]ACTP labeling doubled. We suggest that this represents a sulfhydryl group exposed following the interaction of GRK2 and phospholipid. This hypothesis is further supported by three observations. First, the increase in [I]ACTP incorporation secondary to phospholipid exposure is completely blocked in the presence of MgATP. Second, the V-8 proteolytic map of [I]ACTP-labeled GRK2 identifies two unique bands in the presence of phospholipid that are diminished under basal conditions or in the presence of MgATP. Finally, lipids, which have been shown to activate GRK2, also increased the [I]ACTP incorporation. More importantly, PIP(2), which binds GRK2 but results in an inhibition of catalytic activity completely abolished any [I]ACTP labeling, including what appears to be the site labeled in the absence of lipids. At this time, our working hypothesis is that the sulfhydryl group(s) exposed following phospholipid interaction with GRK2 is near the ATP binding site and/or catalytic groove of the kinase and protected from ACTP labeling by the binding of MgATP. Furthermore, our ability to label this additional site serves as a probe of a putative conformational change, which occurs as the kinase is activated by regulatory lipids.

Data presented in this manuscript provide the first direct evidence to support the direct regulation of GRK2 by lipid. The effect on catalytic activity, in addition to the membrane localization, which occurs via the interaction between various lipids and the pleckstrin homology domain of GRK2 and GRK3, have clear implications as to the regulation of the kinase. Given the apparent association of several members of the GRK family with phospholipid membranes, it is tempting to speculate that many of the GRKs require phospholipid for maximal catalytic activity. While several different types of interaction between various GRKs and phospholipid membranes have been described, it will prove valuable to test whether a common molecular mechanism exists among this family of kinases. We are currently mapping the sites of ACTP incorporation in GRK2 to permit such a study. Additional studies are ongoing to define specific phospholipid interactions with betaARK and extend the current studies to other members of the GRK family.


FOOTNOTES

*
This research was supported in part by Grants GM47120 (to J. J. O.), GM44944 (to J. L. B.), and GM33138 (to A. E. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: University of Wisconsin-Madison, 4285 MSC, 1300 University Ave., Madison, WI 53706. Tel.: 608-262-6078; Fax: 608-263-4969.

(^1)
The abbreviations used are: beta-adrenergic receptor; betaARK, beta-adrenergic receptor kinase; G protein, guanine nucleotide-binding protein; GRK, G protein-coupled receptor kinase; [I]ACTP, N-3-[I]iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)cysteine; PIP(2), phosphatidylinositol 4,5-bisphosphate; PAGE, polyacrylamide gel electrophoresis.

(^2)
J. J. Onorato, unpublished observation.


REFERENCES

  1. Yarfitz, S., and Hurley, J. B. (1994) J. Biol. Chem. 269,14329-14332 [Free Full Text]
  2. Dohlman, H. G., Thorner, J., Caron, M. G., and Lefkowitz, R. J. (1991) Annu. Rev. Biochem. 60,653-688 [CrossRef][Medline] [Order article via Infotrieve]
  3. Gomez, J., and Benovic, J. L. (1992) in Molecular Biology of Receptors and Transporters: Receptors (Friedlander, M., and Muekler, M., eds) pp. 1-34, Academic Press, New York
  4. Sibley, D. R., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1987) Cell 48,913-922 [Medline] [Order article via Infotrieve]
  5. Benovic, J. L., Onorato, J. J., Caron, M. G., and Lefkowitz, R. J. (1990) Soc. Gen. Physiol. 45,87-103
  6. Inglese J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268,23735-23738 [Free Full Text]
  7. Fowles, C., Sharma, R., and Akhtar, M. (1988) FEBS Lett. 238,56-60 [CrossRef]
  8. Palczewski, K., Buczylko, J., Kaplan, M. W., Polans, A. S., and Crabb, J. W. (1991) J. Biol. Chem. 266,12949-12955 [Abstract/Free Full Text]
  9. Chen, C. Y., Dion, S. B., Kim, C. M., and Benovic, J. L. (1993) J. Biol. Chem. 268,7825-7831 [Abstract/Free Full Text]
  10. Haga, K., and Haga, T. (1990) FEBS Lett. 268,43-47 [CrossRef][Medline] [Order article via Infotrieve]
  11. Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992) Science 257,1264-1267 [Medline] [Order article via Infotrieve]
  12. Kim, C. M., Dion, S. B., and Benovic, J. L. (1993) J. Biol. Chem. 268,15412-15418 [Abstract/Free Full Text]
  13. Haga, K., Kameyama, K., and Haga, T. (1994) J. Biol. Chem. 269,12594-12599 [Abstract/Free Full Text]
  14. Clapham, D. E., and Neer, E. J. (1993) Nature 365,403-406 [CrossRef][Medline] [Order article via Infotrieve]
  15. Kunapuli, P., Gurevich, V. V., and Benovic, J. L. (1994) J. Biol. Chem. 269,10209-10212 [Abstract/Free Full Text]
  16. DebBurman, S. K., Ptasienski, J., Boetticher, E., Lomasney, J. W., Benovic, J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270,5742-5747 [Abstract/Free Full Text]
  17. Pitcher, J. A., Touhara, K., Payne, E. S., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270,11707-11710 [Abstract/Free Full Text]
  18. Kim, C. M., Dion, S. B., Onorato, J. J., and Benovic, J. L. (1993) Receptor 3,39-55 [Medline] [Order article via Infotrieve]
  19. Bradford, M. M. (1976) Anal. Biochem. 72,248-254 [CrossRef][Medline] [Order article via Infotrieve]
  20. Benovic, J. L., Shorr, R. G. L., Caron, M. G., and Lefkowitz, R. J. (1984) Biochemistry 23,4510-4518 [Medline] [Order article via Infotrieve]
  21. Kunapuli, P., Onorato, J. J., Hosey, M. M., and Benovic, J. L. (1994b) J. Biol. Chem. 269,1099-1105 [Abstract/Free Full Text]
  22. Cerione, R. A., Strulovici, B., Benovic, J. L., Lefkowitz, R. J., and Caron, M. G. (1983) Nature 306,562-566 [Medline] [Order article via Infotrieve]
  23. Laemmli, U. K. (1970) Nature 227,680-685 [Medline] [Order article via Infotrieve]
  24. Dhanasekaran, N., Wessling-Resnick, M., Kelleher, D. J., Johnson, G. L., and Ruoho, A. E. (1988) J. Biol. Chem. 263,17942-17950 [Abstract/Free Full Text]
  25. Onorato, J. J., Palczewski, K., Regan, J. W., Caron, M. G., Lefkowitz, R. J., and Benovic, J. L. (1991) Biochemistry 30,5118-5125 [Medline] [Order article via Infotrieve]
  26. Hausdorff, W. P., Caron, M. G., and Lefkowitz, R. J. (1990) FASEB J. 4,2881-2889 [Abstract]
  27. Bouvier, M., Hausdorff, W. P., DeBlasi, A., O'Dowd, B. F., Kobilka, B. K., Caron, M. G., and Lefkowitz, R. J. (1988) Nature 333,370-373 [CrossRef][Medline] [Order article via Infotrieve]
  28. Lohse, M. J., Lefkowitz, R. J., Caron, M. G., and Benovic, J. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,3011-3015 [Abstract]
  29. Dawson, T. M., Arriza, J. L., Jaworsky, D. E., Borisy, F. F., Attramadal, H., Lefkowitz, R. J., and Ronnett, G. V. (1993) Science 259,825-829 [Medline] [Order article via Infotrieve]
  30. Schleicher, S., Boekhoff, I., Arriza, J. L., Lefkowitz, R. J., and Breer, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,1420-1424 [Abstract]
  31. Ishii, K., Chen, J., Ishii, M., Koch, W. J., Freedman, N. J., Lefkowitz, R. J., and Coughlin, S. R. (1994) J. Biol. Chem. 269,1125-1130 [Abstract/Free Full Text]
  32. Kong, G., Penn, R., and Benovic, J. L. (1994) J. Biol. Chem. 269,13084-13087 [Abstract/Free Full Text]
  33. Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. M. (1988) J. Biol. Chem. 263,6491-6494 [Abstract/Free Full Text]
  34. Strasser, R. H., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83,6362-6366 [Abstract]
  35. Mayor, F., Benovic, J. L., Caron, M. G., and Lefkowitz, R. L. (1987) J. Biol. Chem. 262,6468-6471 [Abstract/Free Full Text]
  36. Chuang, T. T., Sallese, M., Ambrosini, G., Parruti, G., and DeBlasi, A. (1992) J. Biol. Chem. 267,6886-6892 [Abstract/Free Full Text]
  37. Lorenz, W., Inglese, J., Palczewski, K., Onorato, J. J., Caron, M. G., and Lefkowitz, R. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,8715-8719 [Abstract]
  38. Inglese, J., Koch, W. J., Caron, M. G., and Lefkowitz, R. J. (1992) Nature 359,147-150 [CrossRef][Medline] [Order article via Infotrieve]
  39. Pei, G., Tiberi, M., Caron, M. G., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,3633-3636 [Abstract]
  40. Palczewski, K., McDowell, J. H., and Hargrave, P. A. (1988) Biochemistry 27,2306-2313 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.